Norbert Bischofberger

Nor­bert Bischof­berg­er ices a PhI­II AML drug — for the sec­ond time in his ca­reer

Nor­bert Bischof­berg­er went back to his old col­leagues at Gilead to pluck an AML drug off its back shelves and put it in­to the late-stage pipeline at Kro­nos. And last spring he even worked out a short­er Phase III path at the FDA for the SYK in­hibitor us­ing a unique pri­ma­ry end­point.

But it wasn’t enough.

Af­ter the mar­ket closed Tues­day, Bischof­berg­er pulled the plug on the Phase III, be­lea­guered by a host of is­sues “in­clud­ing the op­er­a­tional chal­lenges the com­pa­ny faced in en­rolling a ge­net­i­cal­ly de­fined sub­set of pa­tients in a front-line set­ting, the resid­ual and on­go­ing im­pacts of the COVID-19 pan­dem­ic, and the in­abil­i­ty to ac­ti­vate planned clin­i­cal tri­al sites in Rus­sia and Ukraine.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.